Skip to Content

Library | SiloxysSystem™ Gel

Library > SiloxysSystem™ Gel > SiloxysSystem™ gel (finasteride)
Last updated    | 7 minute read
[object Object]

What is Topical Finasteride, with SiloxysSystem™ gel?

Written by
XYON Medical Team
Clinically reviewed by
Dr. Victor Hasson, MD
Dr. Christina Han, MD, FRCPC
Dr. Simon Pimstone, MD, PhD, FRCPC

Finasteride is the most clinically effective, FDA-approved drug used to combat male pattern baldness, or androgenetic alopecia (AGA). It was initially developed as an oral dose medication and is still widely prescribed in this form to treat AGA.

Taken at the FDA-approved oral dosage, finasteride can successfully enhance the quality, count and density of mature hairs on your scalp. That said, it’s associated with a higher risk of sexual side effects in this form.

Topical formulations generally aim to lower finasteride’s side effect profile by reducing absorption into the bloodstream. But not all topicals are created equal. Most haven’t been formulated to control the rate at which finasteride enters the body, which risks flooding the skin. As a result, many are unsuccessful at preventing excess absorption into the bloodstream and can negatively impact serum DHT levels, a telltale sign that finasteride has entered systemic circulation and poses a greater risk of side effects.

Available by prescription only at XYON, compounded Topical Finasteride, with SiloxysSystem™ Gel elevates the standard of treatment for male pattern hair loss (androgenetic alopecia). This exclusive topical was designed to deliver a higher concentration of the active ingredient directly to the hair follicles. Topical Finasteride, with SiloxysSystem™ Gel can be compounded at up to 2.5% finasteride, far surpassing the concentration of most topical finasteride formulations.

How is XYON able to offer a compounded topical finasteride formulation that can be compounded at a concentration higher than so many others? The short answer lies in our exclusive drug delivery system, SiloxysSystem™ gel. A more detailed explanation can be found below.

Here, we break down XYON’s exclusive nanoparticle drug delivery system

Topical Finasteride, with SiloxysSystem™ Gel was specifically designed to achieve more targeted drug action at the hair follicles with less of an effect throughout the body. In doing so, it can both optimize the therapeutic effect at the scalp and minimize the risk of side effects.

In this article, we unpack the science behind this exclusive drug delivery system so that you can understand how XYON has set a new standard for the medical treatment of AGA.

Topical drug carriers are not created equal

Topical drug vehicles don’t all work in the same way to deliver medications transdermally, or into the body through the skin. Some are designed to penetrate just beyond the outermost layer of skin to achieve a local effect. Others are formulated to push the active ingredient through multiple layers of subcutaneous tissue and into the bloodstream to elicit a more general effect.

Certain layers of subcutaneous tissue contain a high density of blood vessels that pump blood throughout the body. Once at this level, topically-administered drugs are more likely to be absorbed into the bloodstream and can have a more widespread effect throughout the body.

In some cases, this type of systemic distribution is intentional; the therapeutic effects of some topical medications only be achieved once absorption has occurred. But drugs like finasteride can carry a greater risk of side effects after entering the bloodstream.

In clinical trials, topical finasteride formulations consistently achieve a similar therapeutic effect to oral route treatment, with a reduced side effect profile to boot. In fact, a pretty robust body of research supports that finasteride doesn’t actually require absorption to effectively target AGA (Suchonwanit et al. 2020).


Precision drug delivery: SiloxysSystem™ gel

A renowned hair transplant surgeon and XYON founder, Dr. Victor Hasson recognized the need for a precision topical that could reduce the rate at which finasteride is absorbed into the body. The ideal formulation would optimize drug action at the hair follicle and prevent it from having a more widespread effect.

With this motivation, Dr. Hasson designed SiloxysSystem™ gel in consultation with a top cosmetic formulation scientist in Europe.

Used as a vehicle for finasteride, SiloxysSystem™ gel has two functional benefits:

  1. More of the active ingredient is delivered directly to hair follicles to achieve optimum results
  2. Less of the active ingredient makes is absorbed into the bloodstream to minimize the risk of side effects

This patented gel technology creates a mesh-like matrix over the scalp. It releases finasteride in a controlled and steady way over time, effectively limiting movement into deeper layers of tissue.

SiloxysSystem™ gel affords the body time to process finasteride. By reducing the rate of absorption, a higher concentration of the active ingredient can remain within the scalp skin. This exclusive silicone-based gel carrier ensures that finasteride is released at a steady rate from the time of application, allowing it to permeate into internal cell membranes at an optimal rate.

Topical Finasteride, with SiloxysSystem™ Gel

Topical Finasteride, with SiloxysSystem™ Gel is a compounded medicine that targets a leading cause of AGA. Available by physician’s prescription only at XYON, this precision topical formulation combines the unique SiloxysSystem™ gel technology with FDA-approved finasteride at a 2.5% concentration by weight.

The composition of this specific gel reduces the rate at which finasteride is absorbed into the body; the element of control gives Topical Finasteride, with SiloxysSystem™ Gel a clinical advantage over other topical formulations.

This compounded topical medicine contains three key components:

A proprietary gel matrix is the vehicle for liposome-bound finasteride. It creates a concentration gradient that allows for the controlled release of finasteride. Once applied to the body, the concentration of finasteride resting atop the skin is much higher than the concentration within cell layers directly beneath it. The active ingredient is absorbed into the body gradually to even out the difference in concentrations. This prevents a surplus of finasteride from entering the body at once and bypassing the cell layers where it can be most effective.

This water-based suspension itself has three components:

  1. A lab-made, hypoallergenic synthetic creates a permeable sheath and reduces skin irritation at the site of application
  2. A film-forming agent keeps the gel in place and acts as an drug depot, facilitating movement of the active ingredient past the epidermis
  3. Water is the basis of the gel and acts as a solute, combining all components of the formulation

Liposomes promote drug action on a cellular level, right at the hair follicle. The skin is rich in oils called lipids that protect the outermost layer and help control permeation into deeper tissue. Liposomes have an external phospholipid sheath that allows them to move beyond this oil-rich barrier and permeate into cell membranes. Compounded Topical Finasteride, with SiloxysSystem™ Gel contains a multitude of these spherical particles to transport finasteride into cell membranes.

Finasteride is the most clinically effective medication used to treat male pattern hair loss. It belongs to a class of drugs known as 5-alpha reductase inhibitors (5-ARIs). 5-ARIs target dihydrotestosterone (DHT), a male sex hormone strongly tied to AGA.

In elevated concentrations, DHT ‘attacks’ hair follicles, shortening the growth cycle and accelerating the rate of hair loss. Finasteride prevents the synthesis of DHT to lower the concentration throughout your body, successfully intervening the charge on hair follicles.

The FDA-approved dosage for the treatment of AGA is 1mg administered orally. Topical formulations containing finasteride are not endorsed by the FDA but can be obtained from a compounding pharmacy, with a prescription and at the discretion of a licensed physician.

Most often, these compounded topical formulations contain between 0.1%-1.0% finasteride by weight. Coupled with SiloxysSystem™ gel technology, the precision topical medication available through XYON can safely contain a higher concentration of finasteride at 2.5% as less of the active ingredient moves past the skin and into the bloodstream. This higher concentration is necessary to create the gradient required for steady release of the drug.

Driven by results and backed by science

At XYON, our innovation is driven by cutting-edge science and supported by clinical results. It’s critical that all components within Topical Finasteride, with SiloxysSystem™ Gel work together safely and effectively. And it’s even more important that this compounded medicine is backed by clinical data.

Franz Cell diffusion tests are a measure of transdermal absorption. In these controlled tests, Topical Finasteride, with SiloxysSystem™ Gel effectively improved retention of the active ingredient within a specific layer of skin.

Clinical pharmacokinetic (PK) results have also indicated a reduced impact on overall DHT and testosterone levels in circulation, supporting that finasteride’s side effect profile can be minimized with this specific gel formulation.

At XYON, we pride ourselves in delivering unique, topical solutions founded in medical science. Used as a vehicle for finasteride, SiloxysSystem™ gel has an advantage over other topical formulations.

Consult with one of XYON's specialist dermatologists to determine if Topical Finasteride, with SiloxysSystem™ Gel is right for you. This compounded prescription medication is not suitable for everyone.


References

14.3: Phospholipids in Cell Membranes. (2016, August 5). Chemistry LibreTexts. https://chem.libretexts.org/Courses/University_of_Kentucky/UK%3A_CHE_103_-_Chemistry_for_Allied_Health_(Soult)/Chapters/Chapter_14%3A_Biological_Molecules/14.3%3A_Phospholipids_in_Cell_Membranes

Akbarzadeh, A. et al. (2013). Liposome: classification, preparation, and applications. Nanoscale Research Letters, 8(1), 102. https://doi.org/10.1186/1556-276X-8-102

Drake, L. et al. (1999). The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of Dermatology, 41(4), 550–554.

Film forming systems for topical and transdermal drug delivery. (2017). Asian Journal of Pharmaceutical Sciences, 12(6), 487–497. https://doi.org/10.1016/j.ajps.2017.07.004

Gupta, M., & Mysore, V. (2016). Classifications of Patterned Hair Loss: A Review. Journal of Cutaneous and Aesthetic Surgery, 9(1), 3–12. https://doi.org/10.4103/0974-2077.178536

Kaufman, K. D. et al. (1998). Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology, 39(4), 578–589. https://doi.org/10.1016/S0190-9622(98)70007-6

Kochar, P., Nayak, K., Thakkar, S., Polaka, S., Khunt, D., & Misra, M. (2020). Exploring the potential of minoxidil tretinoin liposomal based hydrogel for topical delivery in the treatment of androgenic alopecia. Cutaneous and Ocular Toxicology, 39(1), 43–53. https://doi.org/10.1080/15569527.2019.1694032

Lee, S. W., Juhasz, M., Mobasher, P., Ekelem, C., & Mesinkovska, N. A. (2018). A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in Dermatology : JDD, 17(4), 457–463. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609098/

Minoxidil Topical: Side Effects, Dosages, Treatment, Interactions, Warnings. RxList. Retrieved July 16, 2021, from https://www.rxlist.com/consumer_rogaine_minoxidil_topical/drugs-condition.htm

Rafi, A. W., & Katz, R. M. (2011). Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA. ISRN Dermatology, 2011, 241953. https://doi.org/10.5402/2011/241953

Salisbury, B. H., & Tadi, P. (2021). 5 Alpha Reductase Inhibitors. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK555930/

Shiva. (2019, January 28). What is an API? Freyr - Global Regulatory Solutions and Services Company. https://www.freyrsolutions.com/what-is-an-api

Skin Exposures and Effects | NIOSH | CDC. (2020, February 21). https://www.cdc.gov/niosh/topics/skin/default.html

Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. (2008, December 31). Indian Journal of Dermatology, Venereology and Leprology. https://ijdvl.com/comparing-the-therapeutic-effects-of-finasteride-gel-and-tablet-in-treatment-of-the-androgenetic-alopecia/

Silicone Mythbusting (with Video). (2019, June 1). Lab Muffin Beauty Science. https://labmuffin.com/silicone-mythbusting-with-video/

Suchonwanit, P., Iamsumang, W., & Leerunyakul, K. (2020). Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. Journal of Dermatological Treatment, 0(0), 1–6. https://doi.org/10.1080/09546634.2020.1782324


Legal Disclaimer

The content within this article and XYON’s Knowledge Library is intended to be used for educational purposes only. It is not a substitute for medical advice. You should always con­sult with a licensed healthcare provider for all mat­ters relat­ing to your health. XYON is not compensated for links to third-party sites that appear within this article. The opinions expressed on third-party sites do not reflect the views and opinions of XYON’s medical writers, physicians or the company.

The better hair loss treatment

Expertise at your fingertips

Start your free consultation
A man spreading XYON topical finasteride on his hand

Stay in the Know

Be among the first to learn about exciting exclusive offers and the latest treatment news.

© 2022 XYON Health Inc. All rights reserved.

This webpage is intended only for residents of the United States.